Usa India information vaccine Usa India

Covid jab approval brightens prospects for Cadila earnings

Reading now: 373
www.livemint.com

₹2,400 crore and ₹4,500 crore in FY22 and FY23 and incremental net profit of ₹400 crore and ₹1,000 crore in FY22 and FY23 resulting in 17% and 40% earnings upgrade to our FY22 and FY23 earnings estimates," said analysts at Phillip Capital Institutional Equities in a note.

They expect Cadila to sell close to 83-150 million doses in FY22 and FY23, respectively, and assume a blended price of ₹300 per dose.

Meanwhile, the company also announced receiving approval for the launch of Tofacitinib extended-release tablets of 11 mg and 22 mg in the US.

The 22mg tablet will have a 180-day marketing exclusivity. Though the US market for Tofacitinib is currently more than $2 billion a year, extended-release tablets comprise half of this market, say

Read more on livemint.com
The website covid-19.rehab is an aggregator of news from open sources. The source is indicated at the beginning and at the end of the announcement. You can send a complaint on the news if you find it unreliable.

Related News

DMCA